Literature DB >> 8814167

Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.

A Waha1, A Baumann, H K Wolf, R Fimmers, J Neumann, D Kindermann, K Astrahantseff, I Blümcke, A von Deimling, U Schlegel.   

Abstract

Alterations in the epidermal growth factor receptor (EGFR) and its main ligand, transforming growth factor-alpha (TGF alpha), were investigated for a possible prognostic relevance in 125 astrocytic gliomas (44 World Health Organization (WHO) Grade II, 19 WHO Grade III, and 62 WHO Grade IV tumors). The TGF alpha and EGFR proteins were detected immunohistochemically using monoclonal antibodies. A positive immunoreaction to TGF alpha was detected in 33 (75%) of 44 WHO Grade II astrocytomas, 18 (95%) of 19 WHO Grade III astrocytoma, and 50 (81%) of 62 WHO Grade IV glioblastomas. No correlation between TGF alpha immunoreaction and duration of survival could be found. A positive EGFR immunoreaction was detected in seven (16%) of 44 WHO Grade II astrocytomas, five (26%) of 19 WHO Grade III astrocytomas, and 32 (52%) of 62 WHO Grade IV glioblastomas. Of these gliomas, 97 (26 WHO Grade II, 17 WHO Grade III, and 54 WHO Grade IV gliomas) were examined for EGFR gene amplification using a differential polymerase chain reaction assay. Amplification of the EGFR gene was detected in none of the WHO Grade II astrocytomas, one (6%) of 17 WHO Grade III astrocytomas, and 18 (33%) of 54 WHO Grade IV glioblastomas. Twenty-two of the tumors investigated showed a positive EGFR immunoreaction without detectable gene amplification (five WHO Grade II, four WHO Grade III, and 13 WHO Grade IV tumors). Gene amplification was invariably associated with a positive EGFR immunoreaction. For the entire study group, a strong correlation between EGFR alterations (gene amplification and positive immunoreaction) and survival could be found. However, this correlation only reflected the higher percentages of cases with EGFR alterations in malignant gliomas and was not an independent prognostic factor as determined by multifactorial analysis. These data demonstrate that EGFR alterations are frequent events in astrocytic gliomas and are largely restricted to glioblastomas. However, within one tumor grade they do not provide prognostic information.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814167     DOI: 10.3171/jns.1996.85.4.0634

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  24 in total

Review 1.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

2.  EGFR expression stratifies oligodendroglioma behavior.

Authors:  Craig Horbinski; Jonathan Hobbs; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

3.  Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.

Authors:  A Korshunov; A Golanov; R Sycheva; I Pronin
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  The expression of rho proteins decreases with human brain tumor progression: potential tumor markers.

Authors:  Marie-Annick Forget; Richard R Desrosiers; MaestroRolandaF Del; Robert Moumdjian; Daniel Shedid; France Berthelet; Richard Béliveau
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 6.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Authors:  Balveen Kaur; Fatima W Khwaja; Eric A Severson; Shannon L Matheny; Daniel J Brat; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

7.  TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.

Authors:  J A Kraus; M Wenghoefer; N Glesmann; S Mohr; M Beck; M C Schmidt; R Schröder; U Berweiler; W Roggendorf; S Diete; K Dietzmann; K Heuser; B Müller; R Fimmers; A von Deimling; U Schlegel
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

8.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy.

Authors:  Vladimir Balik; Peter Mirossay; Peter Bohus; Igor Sulla; Ladislav Mirossay; Marek Sarissky
Journal:  Cell Mol Neurobiol       Date:  2009-03-14       Impact factor: 5.046

Review 10.  Epidemiologic and molecular prognostic review of glioblastoma.

Authors:  Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.